Cost-Utility Analysis of Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms
- PMID: 37142802
- DOI: 10.1007/s00270-023-03443-9
Cost-Utility Analysis of Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms
Abstract
Purpose: To perform a post hoc cost-utility analysis of a randomized controlled clinical trial comparing prostatic artery embolization (PAE) and transurethral resection of the prostate (TURP) in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Materials and methods: We conducted a cost-utility analysis over a 5-year period to compare PAE versus TURP from a Spanish National Health System perspective. Data were collected from a randomized clinical trial performed at a single institution. Effectiveness was measured as quality-adjusted life years (QALYs), and an incremental cost-effectiveness ratio (ICER) was derived from the cost and QALY values associated with these treatments. Further sensitivity analysis was performed to account for the impact of reintervention on the cost-effectiveness of both procedures.
Results: At the 1-year follow-up, PAE resulted in mean cost per patient of €2904.68 and outcome of 0.975 QALYs per treatment. In comparison, TURP had cost €3846.72 per patient and its outcome was 0.953 QALYs per treatment. At 5 years, the cost for PAE and TURP were €4117.13 and €4297.58, and the mean QALY outcome was 4.572 and 4.487, respectively. Analysis revealed an ICER of €2121.15 saved per QALY gained when comparing PAE to TURP at long-term follow-up. Reintervention rate for PAE and TURP was 12% and 0%, respectively.
Conclusions: Compared to TURP, in short term, PAE could be considered a cost-effective strategy within the Spanish healthcare system for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. However, in long term, the superiority is less apparent due to higher reintervention rates.
Keywords: Benign prostatic hyperplasia; Cost-effectiveness; Prostatic artery embolization (PAE); Transurethral resection of the prostate (TURP).
© 2023. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Comment in
-
Cost Matters: A Rigorous Economic Analysis of PAE with Comparison to TURP.Cardiovasc Intervent Radiol. 2023 Aug;46(8):1036-1037. doi: 10.1007/s00270-023-03487-x. Epub 2023 Jun 27. Cardiovasc Intervent Radiol. 2023. PMID: 37369822 No abstract available.
References
-
- Gravas S, Cornu JN DM et al. EAU Guidelines: management of non-neurogenic male LUTS [Internet]. 2020. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
